1
The first-line treatment option for HSV-1 infection is acyclovir (ACV) and its analogs, all targeting 23 to the viral DNA polymerase 5 . The effectiveness of these drugs is frequently inadequate and they 24 suffered from (i) frequent drug resistance including emergence of mutants 6-8 , (ii) ineffective for 25 stromal and endothelial infection 4,9,10 , (iii) side effects including nephrotoxicity induced by prolonged 26 use [11] [12] [13] [14] . For better alternatives, antibodies, peptides and small molecular inhibitors are under 27 development 15 . However, none of these strategies are able to disrupt the virus or modulate its 28 reservoir-therefore, incapable of preventing recurrence. 29 CRISPR cleaves on genomes directly and has shown therapeutic potential in a variety of disease 30 models, in most cases genetic diseases [16] [17] [18] [19] [20] [21] . Its therapeutic potential on infectious diseases is 31 promising, but still in its infancy due to lack of strong safety and efficacy evidence supporting for 1 clinical application 22 . So far, no existing studies have shown the therapeutic efficacy of CRISPR in 2 vivo against HSK 23 . 3
In this study, we designed a gRNA expression cassette targeting to two essential genes of HSV-1 -4 UL8 and UL29, simultaneously, and co-packaged with spCas9 mRNA to mRNA-carrying lentiviral 5 particle (mLP) (Fig. 1a, 1b and 1c ). As the resulting lentiviral particle was designed to destroy the 6 genome of HSV-1, we therefore designate it HSV-1-erasing lentiviral particles (HELP). The gRNA 7 expression cassette is reverse transcribed and maintained as circular episomal DNA as integration-8 defective lentiviral vector (IDLV) (Fig. 1b ). As the UL8 gRNA is cloned into the ∆U3 region of long 9 terminal region (LTR), it will be copied from 3'-LTR to 5'-LTR during reverse transcription ( Fig.  10 1b). We produced the HELP by co-transfection of 6 plasmids to 293T cells and harvested the particles 11 by ultracentrifugation ( Fig. 1c ). As controls, we also produced mLP expressing single gRNA-either 12 UL8, UL29 or scramble (non-targeting gRNA). To verify whether HELP was indeed capable of 13 inhibiting HSV-1, 293T cells were transduced with HELP for 24 hr and infected with HSV-1. The 14 supernatants were harvested 1 day and 2 days after HSV-1 infection, respectively, and subjected to 15 virus yield assay. We found inhibitory effects for all viral gene-targeting mLPs with the UL8/UL29 16 co-targeting HELP the most efficient ( Fig. 1d and Supplementary fig. 1 ). We therefore chose HELP 17 in all the subsequent experiments. 18
The HSV-1 infection is sensitive to type I interferons (IFNs)induced by pathogen-associated 19 molecular pattern molecules (PAMPs) even in the absence of gene editing (Supplementary fig. 2) 24 . 20
To exclude the necessity of type I IFNs, here, we evaluated the antiviral activity of HELP in both 21 wild-type and IFNAR2 knockout HaCaT cells. We found HELP significantly inhibited HSV-1 in 22 both cell lines, but not the scramble control ( Fig. 1e and Fig. 1f ). Furthermore, we analysed the UL8 23 and UL29 loci and found indel frequency about 40% for UL8 while only 6% UL29 (Fig. 1g ). The 24 indels on UL29 were relatively low. ICP8 (encoded by UL29) plays a multifunctional role in the viral 25 life cycle including DNA synthesis 25 . Therefore, mutations on UL29 are intolerant and quickly 26 diluted. Indeed, when using plasmids as the target, we obtained even higher indels for UL29 gRNA 27 ( Fig. 1h ). Notably, antiviral activity of HELP is under-estimated using PCR-based indels analysis, 28 since not all the cleavage outcomes can be amplified (Supplementary fig. 3 ). In addition, we found 29 HELP did not provoke innate immune sensing in contrast to HSV-1 strains which were all sensed by 30 THP-1 derived macrophages at MOI=1 and induced moderate, but significant IFN response 31 ( Supplementary fig. 4 ). Together, these data suggest the HELP inhibits HSV-1 through DNA 1 disruption, but not type I IFN-dependent innate immune response. 2 Corneal stroma is highly linked to keratitis recurrence 26 . Stroma are rich of nerve terminals that 3 originate from the trigeminal ganglia (TG) where HSV-1 maintains latancy 27 . Therefore, we explored 4 if HELP was functional in primary corneal stromal cells from mice. The primary stromal cells were 5 transduced with a non-GFP version HELP for 24 hr and then infected with HSV-1. We found HELP 6 potently suppressed the GFP expression as well as viral replication using both low and high MOI on 7 either 24 hr or 48 hr post-infection while the scramble control did not show any protection effects 8 ( Fig. 1i-l) . 9
HSV-1 propagates fast (about 18 hr for the lytic replication cycle), so it could be expected that 10 permanent nuclease presence is necessary to achieve therapeutic efficacy. Paradoxically, persisting 11 nuclease expression may bring additional risks. From a safety perspective, transient nuclease 12 exposure is desired for CRISPR therapeutics. Upon infection, HSV-1 encounters harsh antiviral 13 response from innate and adaptive immunity. Here, we hypothesize that reducing the viral load to a 14 certain level is sufficient to control the virus in vivo. To verify this, we performed dose-response 15 experiments of HSV-1 infection on scarified corneas of mice. Indeed, only when HSV-1 is over 2x10 4 16 PFU, did the viability and weight of mice change and symptoms of keratitis developed 17
(Supplementary fig. 5). 18
We therefore set out to investigate the potential of HELP as a novel HSK therapeutic in vivo. To 19 identify the kinetics of HSV-1 infection in our HSK model, we visualized HSV-1 using confocal 20 imagining and found the virus progressively disseminated from surficial to deep side of corneal 21 stroma during the time from day 2 to 8 post-infection ( Supplementary fig. 6 ). We therefore chose day 22 5 as our endpoint. The experimental set-up is illustrated in Fig. 2a . We first deep-sequenced the on-23 target activity of HELP on HSV-1 genome in murine corneas. The indels induced by HELP was 24 approximately 7% on UL8 loci and 5% for UL29 loci (Fig. 2b ). Next, we performed confocal imaging 25 to access HSV-1 replication and HELP distribution in the corneas of mice, which was represented by 26 viral capsid protein VP5 and GFP, respectively. We found HSV-1 was replicating actively in the 27 corneal stroma in the mock and scramble controls while it was hardly detectible after HELP treatment 28 ( Fig. 2c ). Accordingly, HELP was evenly distributed in all corneal structures-from epithelium and 29 stroma to endothelium ( Fig. 2c ). To assess whether HELP treatment blocks the transmission of HSV-30 1 from corneal epithelium to the peripheral and central nervous system (CNS), eyes, TGs and brain 31 samples from all the infected mice were harvested and examined for the copy number of HSV-1 1 genomes and infectious viruses. In all samples, the viral load was significantly reduced after HELP 2 treatment ( Fig. 2e-2j ). Additionally, we performed confocal imaging of TG and whole brain. In 3 agreement with the qPCR and PFU analysis, we found HELP diminished HSV-1 to almost 4 undetectable level in both TG and brain ( Fig. 2k-2l ). Tissue distribution is an important safety index 5 for in vivo gene therapy. We therefore evaluated the dissemination of HELP in the whole body and 6 found HELP was highly restricted to the eyes, not other organs, including reproductive organs 7 ( Supplementary fig. 7 ). Interestingly, we also detected HELP in the TG though it was factually 8 injected in the corneas supporting retrograde delivery of CRISPR from neuron termini in the corneas 9 to neuron body in the TG (Supplementary fig. 7 ). This finding was further strengthened detection of 10 HELP in the TG by confocal imaging (Fig. 2m ). 11
To mimic the natural disease process of HSK, we adopted a recurrent HSK model in which eyes were 12 infected with HSV-1 to establish latency before of HELP treatment ( Fig. 2n ). We reactivated the mice 13 survived from the acute infection by UV-B irradiation of the eyes 60 days after HSV-1 inoculation. 14 We then treated the eyes with HELP and quantified the HSV-1 genome two days later. Indeed, we 15 found HELP significantly decreased viral DNA in the infected eyes ( Fig. 2o ). Notably, we also found 16 reduced level of HSV-1 reservoir in the TG indicating HELP was able to modulate the viral reservoir 17 in the TG (Fig. 2p ). 18
To determine the disease development and therapeutic efficacy, we monitored the clinical signs of 19 acute ocular herpes infection and scored them in a blinded fashion ( Fig. 3a) . Mice that were treated 20 with HELP did not show any disease progress (n=6 mice) while the mock-treated and scramble gRNA 21 treated eyes developed severe signs of ocular infection ( Fig. 3b and Fig. 3c ). Next, we performed 22 histological staining to examine the pathology of the eye. The mock-and scramble gRNA-treated 23 eyes presented with irregular stroma matrix and increased corneal thickness, typical of acute infection 24 ( Fig. 3d and 3e ). We further found HSV-1 infection in the corneas induced significant type I IFN 25 response, while HELP transduction was not sensed ( Supplementary Fig. 8 ). T-cell mediated 26 destruction is responsible for much of the morbidity in infectious stromal disease in addition to direct 27 viral effects 28 . Using immunohistochemistry, we showed HSV-1 infection leaded to CD4 + and CD8 + 28 cells infiltration in the corneal stroma for the mock and the scramble groups, but HELP treatment 29 prevented immune cell infiltration ( Supplementary Fig. 9 ). We also noticed that PD-L1 was up-30 regulated in the epithelium and stroma of untreated mice after HSV-1 infection in consistent with 31 previous observations ( Supplementary Fig. 9 ) 29 . Increased local PD-L1 expression may inhibit virus 32 clearance by immune cells highlighting the importance of direct DNA degradation by CRISPR. To 1 access the secreted virus, the swabs were titrated every other day post-infection. HELP treatments 2 significantly reduced the viral presence in the eyes (Fig. 3f ). In addition, body weights were recorded 3 every other day from 2 dpi. No loss of body weights was observed for HELP treated mice, while it 4 was evident for the mock and scramble control ( Fig. 3g ). Survival curves were generated for each 5 group to assess the efficacy of the treatments. Notably, all mice survived in the HELP treated groups 6 ( Fig. 3h ). Finally, we examined if intrastromal injection of HELP induces Cas9-specific IgG in the 7 blood stream. We did not observe significantly higher Cas9-specific IgG for both HELP and scramble 8 control than the mock (n=5 mice, non-significant, Student's t-tests). In contrast, when HELP was 9 injected via footpad route, it provoked significantly higher anti-Cas9 IgG in the sera (n=5 mice, 10 P<0.001, Student's t-tests) ( Supplementary Fig. 10 ). Taken together, these results suggest that the 11 administration of HELP significantly reduced the manifestation of disease severity during ocular 12
HSV-1 infection. 13
Having established the therapeutic efficacy of HELP in murine model, we sought to investigate the 14 antiviral potential of HELP in human corneas ( Fig. 4a ). One human cornea was evenly divided into 15 two halves, and injected with either 15 µL HELP (equal to 1.5 µg p24) or PBS, respectively, for 16 confocal imaging. We found HELP was evenly spread in the stroma and potently inhibit HSV-1 17 replication as manifested by viral protein VP5 compared to mock controls ( Fig. 4b-c ). With cornea 18 from another donor, we found HELP treatment significantly diminished both genome of HSV-1 and 19 viral titers ( Fig. 4d-e ). Additionally, we showed that VP5 protein was hardly detectible after HELP 20 treatment by Western blot analysis of corneal samples ( Fig. 4f ). Altogether, our data indicate that 21
HELP efficiently inhibits HSV-1 replication in human corneas from four different donors. 22
Recently, Jaishankar et al. reported BX795-a commonly used inhibitor of TANK-binding kinase 1 23
(TBK1)-blocks HSV-1 infection in vivo by targeting Akt phosphorylation in infected cells 30 . 24
However, BX795 does not eliminate viral DNA and 20% of treated-mice still died within 14 days. 25 Using a similar model, all mice survived after HELP treatment though the death rate was even higher 26 for controls. 27 HELP carries Cas9 in the form of mRNA and has no long-term off-targeting risk troubling other 28 means of CRISPR delivery such as AAV. We show 'hit-and-run' gene editing is sufficient to achieve 29 therapeutic efficacy against HSK in vivo, and block HSV-1 replication in human corneas. 30
Additionally, HELP gRNAs targets to the genome of virus instead of human, which may accelerate 31 it for clinical translation. Modulating virus reservoir is essential to prevent HSK from recurrence. Our 1 study showed preliminary evidence of retrograde transportation of HELP from corneas to TG using 2 VSV-G pseudotyping, however, enhanced retrograde delivery may be achieved by pseudotyping 3 HELP with derivatives of rabies virus glycoprotein, which may further strengthen the efficacy of 4 HELP in clinical studies 31, 32 . 5 6 METHODS 7
Cell cultures and HSV-1 propagation 8
293T, Vero, HaCaT and HaCaT IFNAR2-KO cells were cultured in DMEM (Gibco, USA). DMEM 9 media were supplemented with 10% fetal bovine serum (Gibco, USA) and 1% 10 penicillin/streptomycin (P/S) (Thermo Fisher Scientific, USA). Primary mouse corneal stromal cells 11 were maintained in MEM (Gibco, USA) supplemented with 1% P/S and 10% fetal bovine serum. 12
Human cornea tissues were maintained in MEM (Gibco, USA) supplemented with 1% P/S and 10% 13 fetal bovine serum. All cells were cultured at 37°C and 5% (vol/vol) CO 2 . HSV1 strain 17syn+, 14 mckrea, F, and HSV1-GFP were propagated in and titrated on Vero cells. 15
Production of mLPs 16
293T cells were seeded in 15-cm dishes at a density of 10 7 /dish 24 hr before calcium phosphate 17 transfection. 24 hr after transfection, the media were refreshed, and the supernatants were harvested 18 48 hr and 72 hr post-transfection before passing through a 0.22-µm filter (Millipore, USA) and 19 ultracentrifugation at RPM 25,000 at 4°C for 2 hr. Pellets were re-suspended in PBS and stored at 20 −80°C. To produce 'all-in-one' mLPs, 293T cells were transfected with 9.07 µg pMD.2G, 7.26 µg 21 pRSV-Rev, 15.74 µg pMDlg/pRRE-D64V, 15.74 µg pMS2M-PH-gagpol-D64V, 31.46 µg pCMV-22
Cas9-6XMS2 and 31.46 µg pLV-egfp-U3-osp-gRNA with corresponding gRNA sequence. To 23 produce HELP, pLV-U6-UL29-egfp-U3-UL8 was used as gRNA producing plasmid. To produce 24 non-GFP version HELP, pLV-U6-UL29-U3-UL8 was used. The gene sequences of plasmids were 25 supplied. 26
HSV-1 plaque assay 27
HSV-1 plaque assays were performed in triplicates for each biological sample. 1.5×10 5 Vero cells 28
were seeded in a 12-well plate in the complete DMEM and infected the following day with various 29 dilutions of HSV stocks or culture supernatants. Two hours after infection, cells were overlaid with 30 1% agarose (Sangon, China) solution. After incubation for 3 days, cells were fixed with 4% 1 formaldehyde and stained using 1% crystal violet solution at room temperature for 2 hours. After 3 2 washes with PBS, plates were allowed to dry and the numbers of plaques were counted. Viral titers 3 were calculated as plaque forming units/mL (PFU/mL). 4
Infection of cells 5
For 293T, HaCaT, HaCaT-IFNAR2-KO, THP1 and primary mouse corneal stromal cells, 4×10 4 cells 6 were seeded in a 48-well plate well and transduced with 400 ng mLP on the following day. The media 7
were refreshed 12 hpi. After 24-hr transduction, the cell infected with HSV1-GFP at a MOI of 1. The 8 supernatants were harvested at 24 and 48 hpi for plaque assay, and the DNA isolated from the cell 9 lysates using viral DNA extraction kit (TaKaRa, Japan) was used to determine the cleavage activity 10 of HSV-1 genomes by Sanger sequencing and TIDE analysis. The used primers are shown in the 11 Supplementary Table 1 . 12
Flow cytometry analysis 13
The primary mouse stromal cells were seeded at a density 4×10 4 /well on day 1, and transduced with 14 UL29-UL8-co-targeting mLP-CRISPR (non-GFP version) on day 2. The cells were then infected 15 with HSV1-GFP on day 3. The GFP signals were determined by flow cytometry (BD & LSR Fortessa) 16
and analysed for the percentage of GFP + cells and mean fluorescence intensity on day 4 and 5. 17
ELISA 18
The p24 of mLP was measured using HIV p24 ELISA according to the manufacturer (Beijing 19
Biodragon Immunotechnologies, China). To detect mouse humoral IgG immune response to Cas9, 20
IgG Mouse ELISA Kit (Abcam, USA) was uses following manufacturer's protocol with a few 21 modifications. A total of 0.25 µg of recombinant Cas9 proteins (Novoprotein, China) suspended in 22 PBS were used to coat 96-well ELISA plates and incubated at 4°C for 12 hr, then washed three times 23 using 1X Wash Buffer. Plates were blocked with 2% BSA Blocking Solution for 2 hr at room 24 temperature, then washed three times. Serum samples were added to each well. The remaining steps 25 were doing as manufacturer's protocol. Cas9 Mouse mAb (Cell Signaling Technology, USA) was 26 used to make a standard curve, the dilution gradient was accorded to the instruction of IgG Mouse 27 ELISA Kit. 28
Western blotting 29
To detect the effect of HSV infected human stromal cornea after treatment with UL29-UL8-targeting 1 mLP-CRISPR. The human cornea stromal tissues were grinded using Tissuelyser with magnetic 2 beads. The suspensions were lysed in RIPA (Beyotime Biotechnology, China) in the presence of a 3 protease inhibitor (Beyotime Biotechnology, China) for 30 minutes and incubated with SDS-PAGE 4 sample loading buffer (Beyotime Biotechnology, China) for 15 minutes at 98°C. The proteins were 5 separated by SDS-polyacrylamide gel electrophoresis and transferred to the PVDF membrane. Membrane was blocked by 5% fat-free milk dissolved in TBS/0.05% Tween-20 for 1 hr. Membrane 7 was cut off according marker and incubated with primary antibody overnight at 4°C. The membranes 8
were incubated with anti-mouse secondary antibodies (Cell Signaling Technology, USA) and 9 visualized by hypersensitive ECL chemiluminescence (Beyotime Biotechnology, China). Actin was 10 used for signal normalization across samples. The primary antibodies used in this experiment were 11 HSV VP5 monoclonal antibody (Santa Cruz Biotechnology, USA) and β-Actin Mouse mAb (Cell 12
Signaling Technology, USA). 13
Quantitative PCR 14
Genomic DNAs and total RNAs from all samples were extracted using Viral DNA/RNA extraction 15 kit (TaKaRa, Japan). cDNA was synthesized using the QuantScript RT Kit (TIANGEN, China) 16
according to the manufacturer's protocol. RT-qPCR was performed using PowerUp SYBR Green 17
Master Mix (Applied Biosystems, USA) following the manufacturer's protocol. For HSV-1 genome 18 quantification in mouse eye, trigeminal ganglion and brain, genomic DNAs were extracted from the 19 eye, trigeminal ganglion and brain. qPCR was performed to detect HSV-1 (primer Y5/Y6) which was 20 then normalized to GAPDH (SK13/SK14). To detect HSV-1 relative expression in human cornea and 21 mouse model of recurrent HSK, total RNA was extracted. RT-qPCR was performed using primers 22 Y5/Y6, then normalized to human GAPDH (SK55/SK56) or mouse GAPDH (SK13/SK14). To detect 23 mLP distribution in vivo, genomic DNAs were extracted from eye, trigeminal ganglion, heart, liver, 24 spleen, lung, kidney and testis. qPCR was performed to detect WPRE (primer SK9/SK10) which was 25 then normalized to GAPDH (SK13/SK14). To detect immunoreaction induced by HSV1 in mouse, 26 total RNA was extracted from eyes. RT-qPCR was performed to detected ISG15 (SK51/SK52), RIG1 27 (Y7/Y8) and IFNB1 (Y9/Y10) which was then normalized to GAPDH (SK13/SK14). To detect 28 immunoreaction induced by HSV1 in cells THP1 and induced by HELP in cells HaCat, total RNA 29 was extracted. RT-qPCR was performed to detected ISG15 (Y11/Y12), RIG1 (Y13/Y14) and IFNB1 30 (Y15/Y16) which was then normalized to GAPDH (SK55/SK56). The used primer sequences were 31 listed in the Supplementary Table 2 . 32
Mice 1 6-8 weeks old, male, specific-pathogen-free (SPF) C57BL/6J mice were used in this study. The mLP 2 or PBS was injected to mice by intrastromal injection under the dissecting microscope. All mouse in 3 this study were complied with the guidelines of the Institutional Animal Care and Use Committee 4 (IACUC) of the Shanghai Jiao Tong University. 5
Intrastromal injection 6
The mice were anesthetized by intraperitoneal injection of 1.25% Avertin (0.2 mL/10 g of body 7 weight). A small intrastromal pocket was carefully created in the mid-peripheral cornea by 29 G 8 needle. Then a 33G syringe was inserted towards the central cornea, and 2 µL mLP or PBS was 9 injected to corneal stroma. Both eyes were injected in this study. 10
Murine acute HSV-1 infection model 11
The mice were anesthetized by intraperitoneal injection of 1.25% Avertin. Corneas were scarified 12 with a 3×3 crosshatch pattern. The mice were inoculated with 2×10 6 PFU HSV-1 17syn+ on both 13 eyes. The body weight and disease scores were measured at the indicated times post infection. The 14
scoring was performed as blinded study: hair loss (0: none, 1: minimal periocular hair loss, 2: 15 moderate periocular hair loss, 3: severe hair loss limited to periocular, 4: hair loss severe and 16 extensive); hydrocephalus (0: none, 1: minor bump, 2: moderate bump, 3: large bump); symptoms 17 related to neurological disease (0: normal, 1: jumpy, 2: uncoordinated, 3: hunched/lethargic, 4: 18 unresponsive/no movement); eye swell/lesions (0: none, 1: minor swelling, 2: moderate swelling, 3: 19 severe swelling and skin lesions, 4: lesions extensive). Mice were sacrificed at the specified times 20 post infection. To collect the eye swabs, mouse eyes were gently proptosed, then wiping a sterile 21 cotton swab (Miraclean Technology, China) three times around the eye in a circular motion and twice 22 across the center of the cornea in an "+" pattern. The cotton swabs were placed in 1 mL of DMEM 23 containing 2% (vol/vol) FBS, 1% P/S and stored at -80℃ until titrated by plaque assay. Serum were 24 collected at 14 dpi to test the mouse humoral IgG immune response to Cas9 by ELISA. Three mouse 25 eyes from each group were processed for histological evaluation. 26
Murine recurrent HSV-1 infection model 27
The mice were inoculated with 2×10 5 PFU HSV-1 17syn+ for both eyes on scarified corneas. Mice 28 survived from acute infection were maintained for 60 days and reactivated by UV-B irradiation of 29 the eyes, followed by HELP treatment. The TGs and eyes were collected to quantify HSV-1 DNA by 1 qPCR. 2
Human cornea HSV-1 infection 3
The human corneas were obtained from fresh cadavers and supplied by Eye, Ear, Nose and Throat 4
Hospital, Fudan University with experiments conducted according to the Declaration of Helsinki and 5 in compliance with China law. The corneas were evenly divided into two halves. One half was dosed 6 with 15 µL HELP by intrastromal injection (equal to 1.5 µg p24) while the other was dosed with PBS 7 by intrastromal injection as a mock control. The corneas were then infected with 2×10 6 PFU of HSV-8 1 17syn+ in MEM medium containing 2% FBS, and the media were refreshed 2 hpi with MEM 9 containing 10% FBS and 5% P/S. Two days after HSV-1 infection, the corneas were processed for 10 immunofluorescence imaging, immunoblotting or DNA isolation by the viral DNA extraction kit to 11 determine the viral genomes by qPCR. The supernatants were collected for plaque assay. 12
Immunofluorescence imaging 13
For confocal imaging, the 293T and mouse cornea stroma cell were imaged under A1Si Laser 14
Scanning Confocal Microscope (Nikon, Japan) at the indicated times. The eyes, trigeminal ganglions 15 and brains were fixed in 4% PFA overnight at 4°C then transfer to 30% sucrose until the tissue sink. 16
All tissues were embedded in OCT Tissue-Tek (Sakura Finetek, USA) and frozen on liquid nitrogen. 17
Sections with 10-µm thickness were cut using the CM1950 (Leica, Germany) freezing microtome 18 and processed for immunofluorescence as mentioned previously. The slides were dried at room 19 temperature for 10 minutes and blocked in blocking buffer with 5% normal donkey serum (Solarbio, 20 China), 1% BSA, 0.3% Triton X-100 in PBS in humidified box at room temperature for 30 minutes. 21
The slides were incubated with the primary antibody against HSV-1 VP5 (Santa Cruz Biotechnology, 22 USA) or GFP (GeneTex, USA) in 1% BSA overnight at 4℃. After washing, the slides were incubated 23 with a secondary antibody (Santa Cruz Biotechnology, USA) in 1% BSA for 1 hour. 24
Deep sequencing 25
The top 5 or 6 predicted off-target sites in human and mouse genome for UL29-targeting and UL8-26 targeting gRNA were identified by Cas-OFFinder online predictor respectively. The on-target and 27 predicted off-target regions were PCR amplified and were pooled by an equal molar ratio for double-28 end sequencing using Illumina MiSeq at Novogene. Raw data of Next-generation sequencing were 29 analysed by online Cas-analyzer. The primer sequences are listed in the Supplementary Table 2 . 30
Histology 1
Mouse eyes were dissected and fixed in paraformaldehyde before embedding in paraffin, sectioning 2 at 10-µm thickness and staining with hematoxylin and eosin. For immunohistochemistry staining, the 3 sections were de-paraffinated and rehydrated followed by incubated with citrate buffer for antigen 4 retrieval. To block endogenous peroxidase activity, the sections were treated by 3% H 2 O 2 for 25 5 minutes. The sections were then blocked with 3% BSA at room temperature for 30 minutes, followed 6 by incubating with anti-CD4+, anti-CD8+ and anti-PD-L1 antibody at 4℃ overnight. The slides were 7 then incubated with a secondary antibody, followed by incubating with the freshly prepared DAB 8 substrate solution to reveal the color of antibody. At last, the tissue slides were counterstained with 9 hematoxylin and blued with ammonia water, and then dehydrated and coverslipped. 
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